Vir Biotechnology (NASDAQ:VIR – Get Rating)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Monday, TipRanks reports. They presently have a $200.00 price target on the stock.
A number of other brokerages have also recently issued reports on VIR. Zacks Investment Research cut Vir Biotechnology from a “hold” rating to a “strong sell” rating in a report on Thursday. TheStreet downgraded Vir Biotechnology from a “c-” rating to a “d+” rating in a report on Monday, March 28th. Robert W. Baird upgraded shares of Vir Biotechnology from an “underperform” rating to a “neutral” rating and decreased their target price for the stock from $36.00 to $28.00 in a report on Thursday, March 3rd. Finally, Needham & Company LLC cut their price target on shares of Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, March 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $67.29.
Shares of VIR traded down $0.53 during midday trading on Monday, hitting $19.82. 38,511 shares of the stock traded hands, compared to its average volume of 1,642,421. Vir Biotechnology has a 1-year low of $20.10 and a 1-year high of $58.00. The firm has a market capitalization of $2.62 billion, a PE ratio of 5.11, a price-to-earnings-growth ratio of 0.33 and a beta of -0.97. The business’s 50 day moving average price is $23.77 and its two-hundred day moving average price is $32.54.
In other Vir Biotechnology news, insider Phillip Pang sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 2nd. The stock was sold at an average price of $34.52, for a total transaction of $172,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 2,393 shares of the firm’s stock in a transaction that occurred on Thursday, February 17th. The shares were sold at an average price of $31.93, for a total value of $76,408.49. The disclosure for this sale can be found here. Insiders sold 30,087 shares of company stock valued at $956,840 over the last three months. 22.40% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. Temasek Holdings Private Ltd lifted its position in Vir Biotechnology by 2.7% during the 3rd quarter. Temasek Holdings Private Ltd now owns 5,761,045 shares of the company’s stock valued at $250,721,000 after purchasing an additional 149,170 shares during the period. BlackRock Inc. increased its position in shares of Vir Biotechnology by 2.9% in the 4th quarter. BlackRock Inc. now owns 5,308,049 shares of the company’s stock valued at $222,248,000 after buying an additional 148,420 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Vir Biotechnology by 0.4% during the fourth quarter. Baillie Gifford & Co. now owns 3,915,501 shares of the company’s stock worth $163,942,000 after purchasing an additional 15,809 shares during the period. Alliancebernstein L.P. raised its holdings in Vir Biotechnology by 22.6% during the 4th quarter. Alliancebernstein L.P. now owns 2,620,753 shares of the company’s stock worth $109,731,000 after buying an additional 483,261 shares during the period. Finally, State Street Corp raised its holdings in shares of Vir Biotechnology by 10.5% during the fourth quarter. State Street Corp now owns 2,528,107 shares of the company’s stock worth $105,852,000 after acquiring an additional 240,241 shares during the period. Hedge funds and other institutional investors own 79.91% of the company’s stock.
About Vir Biotechnology (Get Rating)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
- onsemi Is A Deep-Value In The Chip Sector
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Knight-Swift Transportation Stock is a Logistics Winner
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Why is Chevron Stock Falling After Strong Earnings?
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.